Therapies That Target PCSK9 Effective at Reducing LDL Cholesterol
In a trial published recently in the New England Journal of Medicine, evolocumab, a monoclonal antibody that inhibits circulating PCSK9 (proprotein convertase subtilisin-kexin type 9) by preventing it from binding to the low-density lipoprotein (LDL) receptor, was found to reduce LDL cholesterol and cardiovascular risk in patients with elevated cholesterol despite high-intensity statin therapy. In combination with statin therapy, evolocumab lowered LDL cholesterol levels by 59% from baseline levels compared with placebo, from a median of 92 mg/dL to 30 mg/dL. During a median of 26 months of follow-up, evolocumab was also associated with a 15% reduction in the risk of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. Adverse events were similar between the study groups..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:317 |
|---|---|
| Enthalten in: |
The journal of the American Medical Association / Englische Ausgabe - 317(2017), 20, Seite 2054-2054 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Slomski, Anita [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1001/jama.2017.5656 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1994213728 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1994213728 | ||
| 003 | DE-627 | ||
| 005 | 20230715052715.0 | ||
| 007 | tu | ||
| 008 | 170721s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jama.2017.5656 |2 doi | |
| 028 | 5 | 2 | |a PQ20170901 |
| 035 | |a (DE-627)OLC1994213728 | ||
| 035 | |a (DE-599)GBVOLC1994213728 | ||
| 035 | |a (PRQ)a1126-d5e22bf1a83cb5715956f07f4e8e6280d7c6ad6c0b2dda4fd099f50b96cae0160 | ||
| 035 | |a (KEY)0027940420170000317002002054therapiesthattargetpcsk9effectiveatreducingldlchol | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 100 | 1 | |a Slomski, Anita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapies That Target PCSK9 Effective at Reducing LDL Cholesterol |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a In a trial published recently in the New England Journal of Medicine, evolocumab, a monoclonal antibody that inhibits circulating PCSK9 (proprotein convertase subtilisin-kexin type 9) by preventing it from binding to the low-density lipoprotein (LDL) receptor, was found to reduce LDL cholesterol and cardiovascular risk in patients with elevated cholesterol despite high-intensity statin therapy. In combination with statin therapy, evolocumab lowered LDL cholesterol levels by 59% from baseline levels compared with placebo, from a median of 92 mg/dL to 30 mg/dL. During a median of 26 months of follow-up, evolocumab was also associated with a 15% reduction in the risk of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. Adverse events were similar between the study groups. | ||
| 650 | 4 | |a Death | |
| 650 | 4 | |a Lipoproteins (low density) | |
| 650 | 4 | |a Reduction | |
| 650 | 4 | |a Receptor density | |
| 650 | 4 | |a Binding | |
| 650 | 4 | |a Cerebral infarction | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Statins | |
| 650 | 4 | |a Monoclonal antibodies | |
| 650 | 4 | |a Density | |
| 650 | 4 | |a Angina | |
| 650 | 4 | |a Drug therapy | |
| 650 | 4 | |a Stroke | |
| 650 | 4 | |a Therapy | |
| 650 | 4 | |a Patients | |
| 650 | 4 | |a Subtilisin | |
| 650 | 4 | |a Cholesterol | |
| 650 | 4 | |a Low density lipoprotein | |
| 650 | 4 | |a Myocardial infarction | |
| 650 | 4 | |a Risk | |
| 650 | 4 | |a Health risks | |
| 650 | 4 | |a Kexin | |
| 650 | 4 | |a Medicine | |
| 650 | 4 | |a Cardiovascular diseases | |
| 650 | 4 | |a Infarction | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of the American Medical Association / Englische Ausgabe |d Chicago, Ill. : American Medical Association, 1883 |g 317(2017), 20, Seite 2054-2054 |w (DE-627)129077798 |w (DE-600)2958-0 |w (DE-576)014410338 |x 0254-9077 |7 nnns |
| 773 | 1 | 8 | |g volume:317 |g year:2017 |g number:20 |g pages:2054-2054 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1001/jama.2017.5656 |3 Volltext |
| 856 | 4 | 2 | |u http://dx.doi.org/10.1001/jama.2017.5656 |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1907809275 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_252 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2414 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4082 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4309 | ||
| 951 | |a AR | ||
| 952 | |d 317 |j 2017 |e 20 |h 2054-2054 | ||